Streetbeat News

Earnings

CADL

Candel Therapeutics (NASDAQ:CADL) reported a significant increase in quarterly losses, with Q2 EPS at $(0.74), down from $(0.33) YoY, marking a 124.24% decrease.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:05 pm

URGN

UroGen Pharma ended Q2 2024 with $241.3 million in cash, cash equivalents, and marketable securities.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:04 pm

GALT

Galectin Therapeutics (NASDAQ:GALT) reported a Q2 EPS of $(0.20), missing the analyst consensus estimate of $(0.16) by 25%. This represents a 33.33% increase in losses compared to $(0.15) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm

URGN

UroGen Pharma reported its Q2 2024 financial results, with a GAAP EPS of $(0.91), missing the estimate of $(0.86). Sales were $21.848 million, also missing the estimate of $23.963 million.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm

MLCO

Melco reported an increase in total operating revenues, driven by improved performance in the mass market segment and non-gaming operations, due to the recovery in inbound tourism to Macau in Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:03 pm

NUWE

Nuwellis (NASDAQ:NUWE) reported Q2 2024 GAAP EPS of $(18.85), missing the $(8.24) estimate by 128.76%. However, sales of $2.19M beat the $2.00M estimate by 9.54%, showing a 5.73% increase from last year's $2.08M.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:02 pm

NICE

Over the past three months, 16 analysts have shared their evaluations of NICE (NASDAQ:NICE), revealing a range of outlooks from bullish to bearish. The average 12-month price target has dropped by 8.61% to $266.56. Analysts have adjusted their ratings and price targets, with several lowering their estimates. NICE has shown positive financial performance with a 15.29% revenue growth rate, a net margin of 16.13%, and a strong ROE of 3.13%.

Portfolio Pulse from Benzinga Insights

August 13, 2024 | 12:02 pm

MLCO

Melco Resorts and Enter (NASDAQ:MLCO) reported Q2 sales of $1.160 billion, slightly missing the analyst estimate of $1.161 billion. Despite the miss, sales increased by 22.37% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:01 pm

AILE

iLearningEngines shares are trading higher after the company reported better-than-expected Q2 sales results.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:01 pm

ALUR

Allurion Technologies reported a Q2 EPS of $(0.05), beating the estimate of $(0.24). Sales were $11.77M, surpassing the $10.90M estimate.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 12:01 pm